Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorena Landuzzi

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Molecular Cancer Therapeutics|April 18, 2009
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4Patrizia Nanni, Giordano Nicoletti, Arianna Palladini, et al.
Plos Pathogens|February 6, 2013
Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirusPatrizia Nanni, Valentina Gatta, Laura Menotti, et al.
Molecular Cancer Therapeutics|October 20, 2021
Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 ActivityTommaso Balestra, Maria Cristina Manara, Maria Antonella Laginestra, et al.
International Journal of Cancer|June 23, 2009
Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP)Diana Zambelli, Monia Zuntini, Filippo Nardi, et al.
Cancer Research|October 7, 2010
In silico modeling and in vivo efficacy of cancer-preventive vaccinationsArianna Palladini, Giordano Nicoletti, Francesco Pappalardo, et al.
Proteomics|October 20, 2010
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model systemStefania Croci, Christian V Recktenwald, Rudolf Lichtenfels, et al.
Vaccine|May 12, 2009
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacyCarla De Giovanni, Giordano Nicoletti, Lorena Landuzzi, et al.
Breast Cancer Research : BCR|May 23, 2015
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesisStefania Croci, Patrizia Nanni, Arianna Palladini, et al.
Cancer Research|June 3, 2004
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccineCarla De Giovanni, Giordano Nicoletti, Lorena Landuzzi, et al.
Molecular Biology of the Cell|January 20, 2006
CD99 acts as an oncosuppressor in osteosarcomaMaria Cristina Manara, Ghislaine Bernard, Pier-Luigi Lollini, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|April 18, 2009
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4Patrizia Nanni, Giordano Nicoletti, Arianna Palladini, et al.
Plos Pathogens|February 6, 2013
Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirusPatrizia Nanni, Valentina Gatta, Laura Menotti, et al.
Molecular Cancer Therapeutics|October 20, 2021
Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 ActivityTommaso Balestra, Maria Cristina Manara, Maria Antonella Laginestra, et al.
International Journal of Cancer|June 23, 2009
Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP)Diana Zambelli, Monia Zuntini, Filippo Nardi, et al.
Cancer Research|October 7, 2010
In silico modeling and in vivo efficacy of cancer-preventive vaccinationsArianna Palladini, Giordano Nicoletti, Francesco Pappalardo, et al.
Proteomics|October 20, 2010
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model systemStefania Croci, Christian V Recktenwald, Rudolf Lichtenfels, et al.
Vaccine|May 12, 2009
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacyCarla De Giovanni, Giordano Nicoletti, Lorena Landuzzi, et al.
Breast Cancer Research : BCR|May 23, 2015
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesisStefania Croci, Patrizia Nanni, Arianna Palladini, et al.
Cancer Research|June 3, 2004
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccineCarla De Giovanni, Giordano Nicoletti, Lorena Landuzzi, et al.
Molecular Biology of the Cell|January 20, 2006
CD99 acts as an oncosuppressor in osteosarcomaMaria Cristina Manara, Ghislaine Bernard, Pier-Luigi Lollini, et al.
Pageof 9